Viewing Study NCT05374512


Ignite Creation Date: 2025-12-26 @ 11:07 AM
Ignite Modification Date: 2025-12-31 @ 9:34 PM
Study NCT ID: NCT05374512
Status: ACTIVE_NOT_RECRUITING
Last Update Posted: 2025-11-03
First Post: 2022-04-19
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)
Sponsor: AstraZeneca
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module References Module